Company Active LTD

Company profile

Electronrx Limited

electronRx | Paving the way for personalised digital medicine | Cambridge, UK

electronRx is a deep tech company based in Cambridge, UK, developing novel chronic disease and hospital patient management solutions. We are building the interface between technology, the human body and healthcare organisations that will transform how we deliver healthcare and treat disease.

CRN
10664862
Founded
2017
Age
9

Overview

Legal name
ELECTRONRX LIMITED
Region
East of England
Registered address
C/O MISHCON DE REYA
FOUR STATION SQUARE
CAMBRIDGE
CAMBRIDGESHIRE
UNITED KINGDOM
CB1 2GE
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

25 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

11 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

17 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts PDF pending

AA | Transaction MzQzOTUzMzQyNGFkaXF6a2N4 | Paper/PDF filed

Published 18 Oct 2024 11:51

10 Mar
2017

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2021
Funded years
2021
Age at first award
3 years

Projects

2021 Collaborative R&D Lead participant

Novel wearable neurostimulation system to target period pain

1 May 2021 to 31 Oct 2022

Awarded
£224,100
Total cost £498,001

**Problem** It is calculated that 80% of women of reproductive age (1.5bn people worldwide) suffer from period pain at some point in their life. The pain is felt as either intense spasms or dull and constant cramps in the abdomen which can spread to the back and thighs. Most women suffer the pain in silence, however it disrupts their daily and working liv...

2021 Study

Vagus nerve stimulator and recorder for epilepsy treatment

1 Mar 2021 to 29 Feb 2024

Awarded
£0
Total cost £0

The global Vagus Nerve Stimulation (VNS) market was $505.2 million USD in 2018, it is expected to have a compound annual growth rate of 11.4% till 2026, reaching $1,195 million. VNS is part of the larger neurostimulation market, which incorporates many different stimulation techniques to combat a range of different conditions. The first VNS for refractory...

Product types

Collaborative R&D Study